Electronic Nose Discriminates Prostate Cancer From BPH

Share this content:
Electronic Nose Discriminates Prostate Cancer From BPH
Electronic Nose Discriminates Prostate Cancer From BPH

(HealthDay News) -- The ChemPro 100-electronic nose can discriminate prostate cancer from benign prostatic hyperplasia using urine headspace, according to a study published in The Journal of Urology.

Antti Roine, MD, from the University of Tampere in Finland, and colleagues investigated the ability of an electronic nose (ChemPro 100-eNose) to discriminate prostate cancer from benign prostatic hyperplasia using urine sample headspace. 

RELATED: Surgery May Improve Survival in Younger Prostate Cancer Patients

Performance was tested with samples from 50 patients with confirmed prostate cancer scheduled to undergo robotic assisted laparoscopic radical prostatectomy and 24 samples from 15 patients with benign prostatic hyperplasia scheduled to undergo transurethral resection of the prostate. Urine samples were provided preoperatively, and those with benign prostatic hyperplasia also provided samples postoperatively to be used as a pooled control population.

The researchers found that the eNose reached a sensitivity of 78% and a specificity of 67% using leave-one-out cross-validation. The area under the receiver operating characteristic curve was 0.77.

"The electronic nose is capable of rapidly and noninvasively discriminating prostate cancer and benign prostatic hyperplasia using urine headspace in patients undergoing surgery," the researchers wrote.

One author disclosed financial ties to Amgen, Astellas, Sanofi-Aventis, and Bayer.

Reference

  1. Roine A, Veskimäe E, Tuokko A, et al. Detection of Prostate Cancer by an Electronic Nose: A Proof of Principle Study. J Urol. 2014;doi:10.1016/j.juro.2014.01.113.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs